Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1.

Stefan A Ljunggren, Johannes H M Levels, Kees Hovingh, Adriaan G Holleboom, Menno Vergeer, Letta Argyri, Christina Gkolfinopoulou, Angeliki Chroni, Jeroen A Sierts, John J Kastelein, Jan Albert Kuivenhoven, Mats Lindahl, Helen Karlsson

Journal: Biochimica et biophysica acta 2015;1851(12):1587-95

PMID: 26454245

Abstract

The scavenger receptor class B type 1 (SR-B1) is an important HDL receptor involved in cholesterol uptake and efflux, but its physiological role in human lipoprotein metabolism is not fully understood. Heterozygous carriers of the SR-B1(P297S) mutation are characterized by increased HDL cholesterol levels, impaired cholesterol efflux from macrophages and attenuated adrenal function. Here, the composition and function of lipoproteins were studied in SR-B1(P297S) heterozygotes.Lipoproteins from six SR-B1(P297S) carriers and six family controls were investigated. HDL and LDL/VLDL were isolated by ultracentrifugation and proteins were separated by two-dimensional gel electrophoresis and identified by mass spectrometry. HDL antioxidant properties, paraoxonase 1 activities, apoA-I methionine oxidations and HDL cholesterol efflux capacity were assessed.Multivariate modeling separated carriers from controls based on lipoprotein composition. Protein analyses showed a significant enrichment of apoE in LDL/VLDL and of apoL-1 in HDL from heterozygotes compared to controls. The relative distribution of plasma apoE was increased in LDL and in lipid-free form. There were no significant differences in paraoxonase 1 activities, HDL antioxidant properties or HDL cholesterol efflux capacity but heterozygotes showed a significant increase of oxidized methionines in apoA-I.The SR-B1(P297S) mutation affects both HDL and LDL/VLDL protein compositions. The increase of apoE in carriers suggests a compensatory mechanism for attenuated SR-B1 mediated cholesterol uptake by HDL. Increased methionine oxidation may affect HDL function by reducing apoA-I binding to its targets. The results illustrate the complexity of lipoprotein metabolism that has to be taken into account in future therapeutic strategies aiming at targeting SR-B1.

Copyright © 2015 Elsevier B.V. All rights reserved.

Address: Occupational and Environmental Medicine Center, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece. Electronic address: [email protected].; Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece. Electronic address: [email protected].; Institute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. Electronic address: [email protected].; Department of Pediatrics, section for Molecular Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: [email protected].; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Electronic address: [email protected].; Occupational and Environmental Medicine Center, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.